Havemeyer Place LP purchased a new position in shares of Cencora, Inc. (NYSE:COR – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 7,204 shares of the company’s stock, valued at approximately $2,433,000.
Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Cencora by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after acquiring an additional 221,570 shares in the last quarter. State Street Corp grew its stake in shares of Cencora by 9.3% during the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company’s stock worth $2,872,249,000 after acquiring an additional 782,911 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Cencora by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock worth $1,843,268,000 after acquiring an additional 169,055 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Cencora by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock worth $1,461,965,000 after acquiring an additional 821,098 shares in the last quarter. Finally, Boston Partners grew its stake in shares of Cencora by 2.0% during the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after acquiring an additional 89,506 shares in the last quarter. 97.52% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several research firms have recently commented on COR. Evercore set a $360.00 price objective on Cencora in a report on Wednesday, April 8th. JPMorgan Chase & Co. increased their price objective on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Morgan Stanley set a $342.00 price objective on Cencora in a report on Friday, May 8th. Barclays increased their price objective on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Finally, Citigroup cut their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $380.25.
Cencora Trading Up 1.7%
NYSE COR opened at $274.94 on Friday. The company has a market cap of $53.49 billion, a PE ratio of 21.08, a PEG ratio of 1.48 and a beta of 0.59. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The stock has a 50 day moving average of $292.70 and a 200-day moving average of $330.55.
Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. During the same period in the prior year, the business earned $4.42 EPS. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.
Cencora announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.
Cencora Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is currently 18.40%.
Cencora Profile
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Read More
- Five stocks we like better than Cencora
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
